Welcome to our dedicated page for Puretech Health news (Ticker: PRTC), a resource for investors and traders seeking the latest updates and insights on Puretech Health stock.
PureTech Health plc (PRTC) generates a steady flow of news as a hub-and-spoke biotherapeutics company advancing multiple clinical-stage programs through its own R&D engine and its Founded Entities. Company announcements frequently highlight clinical data, regulatory interactions, portfolio updates, and strategic developments tied to its capital-efficient model.
Recent news releases describe PureTech’s work in idiopathic pulmonary fibrosis via deupirfenidone (LYT-100), which is being advanced toward Phase 3 development by its Founded Entity Celea Therapeutics. Updates have included Phase 2b ELEVATE IPF trial results, open-label extension data, and sub-analyses in older patient populations, as well as regulatory meetings and planning for a pivotal Phase 3 trial. These stories provide insight into how PureTech and Celea are positioning deupirfenidone as a potential new standard of care in fibrotic lung disease.
News items also cover hematologic oncology through Gallop Oncology, another PureTech Founded Entity. Gallop has reported initial topline results from a Phase 1b trial of LYT-200 in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, including safety findings, response rates, and plans for a potentially registrational Phase 2 trial. Additional releases describe ongoing data presentations at major scientific meetings and continued maturation of survival data.
Beyond respiratory and oncology programs, PureTech’s news feed features updates from Seaport Therapeutics, such as the dosing of the first participant in a Phase 1 study of GlyphAgo (SPT-320) for generalized anxiety disorder, as well as corporate developments like leadership changes, half-year financial reports, and conference presentations including appearances at the J.P. Morgan Healthcare Conference. Investors and followers of PRTC can use this news page to track clinical milestones, strategic shifts, and the evolution of PureTech’s portfolio across its hub-and-spoke structure.
PureTech Health (LSE:PRTC) announced that its Founded Entity, Sonde Health, has raised $19.25 million in a Series B funding round. This capital will support Sonde's efforts in enhancing its vocal biomarker platform for health monitoring across multiple conditions like asthma and mental health issues. With a total of $35.25 million raised to date, Sonde aims to expand its commercial growth, new health condition applications, and geographical reach, capitalizing on its vast voice dataset of over 1.2 million samples.
PureTech Health has announced the nomination of LYT-310, an oral cannabidiol (CBD) prodrug developed from the Glyph™ platform. LYT-310 shows a three to fourfold increase in oral bioavailability compared to unmodified CBD, which could enhance its therapeutic application across various age groups and indications, including epilepsy. Clinical studies are expected to commence in Q4 2023. This advancement builds on the company's Glyph platform, aimed at improving the oral administration of therapeutics with limited bioavailability.
PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) announced participation in two investor conferences. Management members will engage in fireside chats at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 1:30 p.m. EST, and the Evercore ISI 5th Annual HealthCONx Conference on November 30, 2022, at 8:50 a.m. EST. The webcasts of these events will be accessible on their investor site. PureTech is focused on innovative biotherapeutics aimed at transforming treatment for serious diseases.
PureTech Health plc (LSE:PRTC, Nasdaq:PRTC) has announced that its CEO, Daphne Zohar, and CMO, Julie Krop, will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 3:50 PM GMT / 10:50 AM EST. The event will be webcasted, and attendees can access the presentation via the company’s investor relations website. PureTech is focused on innovative therapies to transform treatment for serious diseases, boasting a pipeline of 27 therapeutic candidates, including some with FDA clearance.
Vedanta Biosciences, a clinical-stage biopharmaceutical company, announced that Bernat Olle, CEO, will present at the 9th International Human Microbiome Consortium Congress in Kobe, Japan from November 8-10, 2022. The presentation, titled Development of a Defined Bacterial Consortium for the Prevention of Recurrent Clostridioides Difficile Infection, will showcase Phase 2 results of VE303, a therapeutic candidate for preventing recurrent Clostridioides difficile infection, which showed a 31.7% absolute risk reduction in recurrence compared to placebo.
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) announced participation in the Credit Suisse 31st Annual Healthcare Conference on November 8, 2022, at 12:50pm PST / 3:50pm EST. Executives Bharatt Chowrira, Ph.D., J.D., and Julie Krop, M.D., will engage in a fireside chat. The event will be webcast at investors.puretechhealth.com. PureTech is focused on innovative biotherapeutics, boasting a diverse pipeline of 27 therapeutic candidates, including FDA-cleared products.
PureTech Health plc (LSE:PRTC, Nasdaq:PRTC) has announced that its CEO, Daphne Zohar, and CMO, Julie Krop, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference in New York City on September 14, 2022, at 2:05 PM EDT. The event will be available via webcast at investors.puretechhealth.com. PureTech continues to advance its extensive pipeline of 27 therapeutics, with some achieving FDA clearance and European marketing authorization.
PureTech Health announced that data from a Phase 1 crossover trial of LYT-100 indicates improved tolerability compared to pirfenidone, supporting dose selection for the Phase 2 trial in patients with idiopathic pulmonary fibrosis (IPF). The Phase 1 trial showed a 50% reduction in gastrointestinal adverse events and a 45% reduction in nervous system treatment-emergent adverse events. The Phase 2 trial, aimed at establishing safety and efficacy, initiated in June 2022. LYT-100, a deuterated form of pirfenidone, is expected to improve patient compliance and outcomes.
PureTech Health plc announces a multi-year partnership with Koye Pharmaceuticals to develop a vocal biomarker for chronic obstructive pulmonary disease (COPD) in India. This collaboration represents Sonde Health's first agreement with a pharmaceutical firm. Utilizing Sonde's vocal biomarker platform, the aim is to enhance monitoring and treatment of COPD patients through voice technology. COPD is a significant health issue in India, accounting for 13% of deaths. The partnership seeks to leverage advanced technology to improve patient outcomes.
PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) is set to announce its half-yearly results for the six months ending June 30, 2022, on August 25, 2022. The Company will host a presentation and conference call for analysts and shareholders at 9:00 am EDT. PureTech is focused on developing innovative therapeutics for serious diseases, boasting a diverse pipeline of 27 therapeutic candidates, including two with FDA clearance and European marketing authorization.